ArticleHaematologica2024

A multicenter, phase Ib study of subcutaneous administration of isatuximab in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma.

Hang Quach et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.